Prostate Osteoblast-Like Cells: A Reliable Prognostic Marker of Bone Metastasis in Prostate Cancer Patients

Figure 1

Immunohistochemical analysis of vimentin, BMP-2, and PTX-3. (a) Graph shows the number of vimentin-positive prostate cells in BL, BM+, and BM− lesions. (b) Vimentin-positive prostate cancer cells in BM− lesions (scale bar represents 50 µm). (c) Image shows numerous vimentin-positive prostate cancer cells in BM+ lesions (scale bar represents 50 µm). (d) Graph shows the number of BMP-2-positive prostate cells in BL, BM+, and BM− lesions. (e) BM+ lesion displaying numerous BMP-2-positive cancer cells (scale bar represents 50 µm). (f) BMP-2-positive prostate cancer cells in BM+ lesions (scale bar represents 50 µm). (g) Graph shows the number of PTX-3-positive prostate cells in BL, BM+, and BM− lesions. (h) Rare PTX-3-positive cells in BM− lesions (scale bar represents 50 µm). (i) Image shows several PTX-3-positive prostate cancer cells in BM+ (scale bar represents 50 µm).

(a)

(b)

(c)

(d)

(e)

(f)

(g)

(h)

(i)